Table of Contents

Overview.- Pharmacoepidemiology of Diabetes.- New Definitions of Diabetes: Consequences.- Pharmacotherapy of Diabetes.- The Insulin Resistance Syndrome: Concept and Therapeutic Approaches.- Medical Emergencies – Diabetic Ketoacidosis and Hyperosmolar Hyperglycaemia.- Notes on the Use of Glucagon in Type 1 Diabetes.- Insulin and New Insulin Analogues, Insulin Pumps and Inhaled Insulin in Type 1 Diabetes.- Insulin and New Insulin Analogues with Focus on Type 2 Diabetes.- The Place of Insulin Secretagogues in the Treatment of Type 2 Diabetes in the Twenty-First Century.- Metformin – from Devil to Angel.- The Glitazones, Lessons so Far.- Antidiabetic Combination Therapy.- The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors).- The Role of Alpha-Glucosidase Inhibitors (Acarbose).- Multifactorial Intervention in Type 2 Diabetes.- Treating the Comorbid Patient.- Obesity and Pharmacological Treatment.- Management of Diabetic Dyslipidaemia.- Coronary Intervention and Ischemic Cardioprotection in Diabetic Patients.- Diabetic Complications and Side-effects.- ACE-I and ARB and Blood Pressure Lowering, Including Effect on Renal Disease. Treatment of Advanced Diabetic Renal Disease.- Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes.- Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications.- Diabetic Foot Ulcers.- Pharmacotherapy in Diabetic Neuropathy.- Pregnancy – Pharmacological Problems.- Pharmacotherapy of Diabetic Retinopathy.- Pharmacotherapy in Diabetic Sexual Dysfunction.- A Bone Perspective.- Notes from Major Pharmaceutical Companies (all major companies asked to participate).- Achieving Guideline Control with New Pharmacotherapies:Albumin-Binding by Acylation of Insulin and GLP-1.- Pharmacotherapy of Diabetes.